A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer

Clinical trial NCT07226427 · RECRUITING

Trial details

NCT number: NCT07226427
Sponsor: Stemline Therapeutics, Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Platinum-resistant Ovarian Cancer

Start date: 2026-01-10
Primary completion: 2027-12-02
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.